Fibrocell Science, Inc. Appoints Advisors with Expertise in Periodontal/Regenerative Dentistry and Burn Care

- Company Continues Evaluation of Broad Use of Proprietary Autologous Cell Therapy -

Jun 24, 2010, 08:30 ET from Fibrocell Science, Inc.

EXTON, Pa., June 24 /PRNewswire-FirstCall/ -- Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the appointments of Nicolas Elian, D.D.S.; William K. Boss, M.D.; and Daniel D. Lozano, M.D., M.B.A, F.A.C.S. as advisors. As respected dental and medical experts, Drs. Elian and Boss bring deep experience in the study of reconstructive dentistry and fibroblasts, respectively, to their advisory roles for Fibrocell while Dr. Lozano brings expert guidance in the surgical treatment of burns.

"As we continue to work towards our first indication for azficel-T, our novel and autologous cell therapy currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of nasolabial fold wrinkles, the Fibrocell leadership team is charting the path forward for the company's technology," said David Pernock, Chairman and CEO. "Drs. Elian, Boss and Lozano will provide invaluable perspective as we progress with investigating the technology for uses in periodontics and skin repair for burn victims."

Dr. Boss was instrumental in the development of Fibrocell Science's original technology. He has partnered with Dr. Elian to examine its potential applications in the areas of periodontics and reconstructive dentistry.  They believe the novel Fibrocell Science technology may be well suited for periodontal applications such as treating recessive gums, preparing soft gum tissue for dental implants, and preserving tooth extraction sockets.

Dr. Lozano has spent more than a decade helping burn victims. He will provide guidance to the Fibrocell Science team as a clinical path for evaluating the company's fibroblast technology in skin repair following burn damage is developed.

Nicolas Elian, D.D.S.: Expert in Implant Dentistry

Dr. Elian is Assistant Professor and Head of the Division of Implant Dentistry at New York University College of Dentistry (NYUCD) Department of Periodontology and Implant Dentistry. Renown for his expertise in the evaluation and retreatment of implants, Dr. Elian's clinical practice focuses on surgical procedures such as advanced bone grafting and ridge augmentations. He completed his D.D.S degree and post-graduate studies in prosthodontics and implant dentistry at NYUCD. Dr. Elian is currently the Director of the Fellowship Program in Implant Dentistry, and the Director of Experimental Research at NYUCD. He consults on product development for industry manufacturers, and is an inventor and expert in both cell culture and bioengineering. Dr. Elian is Visiting Professor at the University of Chietti, Italy, and Tong Ji University, China, as well as Honorary Professor at El Instututo de Investigaciones Craneo Dento Maxilo Facial de la Facultad de Ciencias de la Salud, Argentina. He is also Adjunct Assistant Professor in the Department of Periodontics at the University of Pennsylvania School of Dental Medicine. Dr. Elian serves on the editorial boards of many peer-reviewed journals and has trained an extraordinary number of specialists and general dentists in the science and surgery of implants.

William K. Boss, M.D.: Expert in Fibroblasts & Autologous Therapy

Certified by the American Board of Plastic Surgery, Dr. Boss has been a practicing surgeon for more than 20 years (currently serving at the Cosmetic Surgery Center). He earned his medical degree at the University of Medicine and Dentistry of New Jersey after graduating Magna Cum Laude from Drew University. In addition, he studied at Harvard University before completing his plastic surgery training at Yale University. Dr. Boss is a frequent lecturer within the medical community in the United States and abroad. He served as Acting Chairman of the Department of Plastic Surgery of Hackensack University and a Clinical Professor at the University of Medicine of New Jersey. Published in numerous academic journals, the work of Dr. Boss has also been featured in several educational videos on surgical techniques.

Daniel D. Lozano, M.D., M.B.A, F.A.C.S.: Expert in Burn Repair

Dr. Lozano is a surgeon at the Surgical Specialists of the Lehigh Valley and also serves as Medical Director of the Regional Burn Center and Chief, Division of Burn for the Lehigh Valley Hospital & Health Network. He earned his medical degree from the University of California San Francisco and his master's degree in business administration from George Washington University. He did his surgical training at the University of Nevada School of Medicine and his burn fellowship at the Regional Burn Center of the University of California San Diego (UCSD) Medical Center, where he also formerly served as clinical instructor, director of clinical burn care and assistant clinical professor of surgery. In addition to his current roles at the Lehigh Valley Hospital & Health Network, he also serves today as assistant professor of surgery at the Penn State College of Medicine. Dr. Lozano has received several awards and honors throughout his career and is a member of numerous medical associations. He also is widely published in the study of surgery, burns and skin repair.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit

Forward-Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, without limitation, whether the Fibrocell Science technology is well suited for periodontal applications. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.

SOURCE Fibrocell Science, Inc.